Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.67 |
| ▸ | GABRD | O14764 | 2/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.67 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.67 |
| ▸ | GABRE | P78334 | 2/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.67 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.67 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.67 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.67 |
| ▸ | NNMT | P40261 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853374 | 0.82 | GABRP (0.72) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| 6-Aminonicotinamide SCHEMBL105510 | 0.80 | NNMT (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29530489 | 0.80 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL42011 | 0.80 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2027693 | 0.80 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11342934 | 0.78 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2442493 | 0.78 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1105486 | 0.78 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30963385 | 0.78 | GABRP (0.96) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL4686219 | 0.78 | GABRP (0.96) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804440-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| CN-1061658-C | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID CO (US) | 2001-02-07 | — | — | CN | disclosed |
| CN-1181084-A | Tricyclic benzazepine vasopression antagonists | AMERICAN CYANAMID CO (US) | 1998-05-06 | — | — | CN | disclosed |
| US-5719278-A | TREATING EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0804440-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | GABRP 157/4885GABRD 1157/4885GABRA1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.